Home › Diffuse Intrinsic Pontine Glioma › Washington
Diffuse Intrinsic Pontine Glioma clinical trials in Washington
10 studies for Diffuse Intrinsic Pontine Glioma are looking for participants at sites in Washington.
Cities in Washington
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Oct 28, 2026 · NCT07680439ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Seattle Children's Hospital, Seattle
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Seattle Children's Hospital, Seattle
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
Ages 2 to 39 · All sexes · Updated Jun 26, 2026 · NCT05009992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Seattle Children's Hospital, Seattle
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
- Seattle Children's Hospital, Seattle
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Seattle Children's Hospital, Seattle
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.